Investigation ofon atopic dermatitis based on gut microbiota and TLR4/MyD88/ NF-κB signaling pathway.

Abstract

BackgroundProbiotics, as common regulators of the gut microbiota, have been used in research to alleviate clinical symptoms of atopic dermatitis (AD).ObjectiveOur research team has previously identified a potential relieving effect ofon the treatment of AD, but the specific mechanism of howalleviates AD has not yet been confirmed.MethodsIn this study, we explored the relieving effect ofon AD throughandexperiments. AD mice induced by 2,4-dinitrofluorobenzene (DNFB) were orally administered with 1 × 10CFU offor three consecutive weeks.ResultsOral administration ofreduced ear swelling, alleviated back skin lesions, decreased mast cell and inflammatory cell infiltration, and regulated the levels of inflammation-related cytokines.activated the intestinal immune system through the TLR4/MyD88/NF-κB signaling pathway, suppressed the expression of inflammatory factors IL-10 and IL-13, and protected the damaged intestinal mucosa.Conclusionadministration improved the diversity and abundance of the gut microbiota, enhanced the functionality of the immune system, and protected the epidermal barrier.